This is how Bern­stein divvies up a $40B Covid-19 vac­cine mar­ket among the lead­ers in the race to an ap­proval

The fren­zied race to reg­u­la­to­ry ap­provals this year is com­ing down to the fin­ish line. The win­ners can im­me­di­ate­ly piv­ot to the com­pe­ti­tion for the mega-block­buster rev­enue gains to come as the start­ing gun is fired for the glob­al race to seize mar­ket share.

Pfiz­er $PFE and their de­vel­op­ment part­ners at BioN­Tech have seized a clear — though small — lead in the race to win FDA ap­proval for the first Covid-19 vac­cine. And the an­a­lyst team work­ing with Bern­stein’s Ron­ny Gal says the phar­ma gi­ant al­so has the mus­cle to seize a clear ad­van­tage in win­ning the biggest slice of the $40 bil­lion mar­ket that lies in wait for the lead­ing play­ers next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA